Use of Wackers sythesis pathway is expected to cut manufacturing costs.

RFS Pharma obtained the rights to use Wacker Chemie’s synthesis pathway for the manufacture of its lead anti-HIV drug Amdoxovir® (DAPD). The compound is currently in Phase II studies.


Wacker reports that its production process should lower costs by creating a more efficient and scalable synthesis for Amdoxovir. “The new process utilizes the 2,6-diamino purine route instead of the 6-chloropurine route used previously,” explains Raymond Schinazi, Ph.D., founder and chairman of RFS Pharma.  “There are a number of patents covered under this agreement and the expiration date of the last patent is 2022, assuming we don’t get any patent extensions.”

Previous articleMabVax Licenses Cancer Vaccine Technology from Sloan-Kettering
Next articleBN ImmunoTherapeutics Inks CRADA with NCI for Prostate Cancer Vaccine Development